Exeltis' global infrastructure and deep market knowledge make them an ideal partner to maximize the impact of our innovative formulation." Salustiano Perez, CEO of Exeltis, adds: " We are thrilled to ...
Exeltis USA, Inc. and other parties (Exeltis) recently prevailed against Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin) in a patent infringement suit brought in the District of Delaware. After a ...
Mumbai, Zug, January 9, 2023: Global pharma major Lupin Limited (Lupin) and Exeltis Healthcare S.L (Exeltis) announced today that the Spanish Ministry of Health (MSCBC) has approved the reimbursement ...
The FDA has torn into Exeltis over a social media sponsored post for birth control pill Slynd, lambasting the drugmaker for leaving out all the risk information, making misleading efficacy claims and ...
Women's health pharma Exeltis USA has been reprimanded by the FDA for making a Facebook post that promoted its birth control product Slynd, overstating its efficacy and failing to mention potential ...
On August 11, 2023, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued an untitled letter to Exeltis USA Inc. (Exeltis) regarding a promotional ...
FLORHAM PARK, N.J., Sept. 16, 2019 /PRNewswire/ -- Exeltis USA, Inc. a division of Insud Pharma (headquartered in Madrid, Spain) today announced the commercial launch of its oral contraceptive tablet ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, has ...
New Delhi: Lupin and Exeltis Healthcare announced that the Spanish Ministry of Health (MSCBC) has approved the reimbursement of Lupin’s NaMuscla (mexiletine) for the symptomatic treatment of myotonia ...
The Pop ulation Council, a global public health research nongovernmental organization (NGO) announced on Wednesday that it has entered into a multi-year agreement with Exeltis, a division of the ...
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Exeltis USA, Inc., a division of the global pharmaceutical group Insud Pharma, today announced “Let’s Love Every Body,” a national campaign designed to empower ...
The deal sets the entry of the Spanish company into the Turkish market and is part of its strategic objective of acquiring an international scale. It will increase Exeltis sales thanks to its improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results